Additionally, there is a correlation between the frequency of LAMA3 promoter methylation in breast tumors and an increase in tumor size and stage.[23] In our study, upregulated EDA2R expression was accompanied by poorer prognosis in patients with breast cancer; nevertheless, additional research demonstrated that EDA2R is implicated in P53-mediated anoikis in tumor cells.[24] To address this contradiction, we conducted a thorough analysis using the KM Plotter database to investigate the association between EDA2R expression and prognosis in various cancers. Here, EDA2R is linked to breast carcinoma.